Literature DB >> 3396613

The effect of cigarette smoking on drug metabolism in the liver and placenta: the use of cotinine in verifying smoking status.

M Pasanen1, K Vahakangas, E A Sotaniemi, O Pelkonen.   

Abstract

Placental and hepatic xenobiotic-metabolising activities were studied in smokers and non-smokers, who were classified by anamnestic interview, plasma thiocyanate and plasma cotinine determinations. Plasma thiocyanate assay is inadequate in the classification of smokers and non-smokers. Plasma cotinine levels reflect more accurately the smoking status. The anamnestic smokers remained smokers and several self-declared non-smokers proved to be smokers. On the basis of plasma cotinine determination all real smokers had higher 7-ethoxyresorufin 0-deethylase (ERDE) activities measured either in placental microsomes or liver biopsy homogenates than non-smokers. Classification based on plasma cotinine levels showed a statistically significant (P less than 0.001) difference between smokers and non-smokers in liver homogenate ERDE activity. However, cotinine levels did not correlate with any of the xenobiotic-metabolising activities tested. An objective biochemical marker, such as cotinine determination seems to be necessary when evaluating the effect of smoking on drug metabolism in man.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3396613     DOI: 10.1007/BF03189927

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  29 in total

1.  Human placental hydroxylation of 3,4-benzpyrene during early gestation and at term.

Authors:  M R Juchau
Journal:  Toxicol Appl Pharmacol       Date:  1971-03       Impact factor: 4.219

2.  Effect of maternal cigarette smoking on 3,4-benzpyrene and N-methylaniline metabolism in human fetal liver and placenta.

Authors:  O Pelkonen; P Jouppila; N T Kärki
Journal:  Toxicol Appl Pharmacol       Date:  1972-11       Impact factor: 4.219

3.  Cigarette smoking and drug metabolism.

Authors:  K Vähäkangas; O Pelkonen; E Sotaniemi
Journal:  Clin Pharmacol Ther       Date:  1983-03       Impact factor: 6.875

4.  Ethoxyresorufin: direct fluorimetric assay of a microsomal O-dealkylation which is preferentially inducible by 3-methylcholanthrene.

Authors:  M D Burke; R T Mayer
Journal:  Drug Metab Dispos       Date:  1974 Nov-Dec       Impact factor: 3.922

5.  The murine Ah locus: in utero toxicity and teratogenesis associated with genetic differences in benzo[a]pyrene metabolism.

Authors:  S Shum; N M Jensen; D W Nebert
Journal:  Teratology       Date:  1979-12

6.  A relationship between cord blood and maternal blood lymphocytes and term placenta in the induction of aryl hydrocarbon hydroxylase activity.

Authors:  O Pelkonen; N T Karki; R Tuimala
Journal:  Cancer Lett       Date:  1981-07       Impact factor: 8.679

7.  Indirect measures of cigarette use: expired-air carbon monoxide versus plasma thiocyanate.

Authors:  S P Fortmann; T Rogers; K Vranizan; W L Haskell; D S Solomon; J W Farquhar
Journal:  Prev Med       Date:  1984-01       Impact factor: 4.018

8.  Aryl hydrocarbon hydroxylase activity in human placenta from cigarette smoking and nonsmoking women.

Authors:  D W Nebert; J Winker; H V Gelboin
Journal:  Cancer Res       Date:  1969-10       Impact factor: 12.701

9.  Genetic and environmental regulation of aryl hydrocarbon hydroxylase in man: studies with liver, lung, placenta, and lymphocytes.

Authors:  O Pelkonen; K Vähäkangas; N T Kärki; E A Sotaniemi
Journal:  Toxicol Pathol       Date:  1984       Impact factor: 1.902

10.  The effect of cigarette smoking on 7-ethoxyresorufin O-deethylase and other monooxygenase activities in human liver: analyses with monoclonal antibodies.

Authors:  O Pelkonen; M Pasanen; H Kuha; B Gachalyi; M Kairaluoma; E A Sotaniemi; S S Park; F K Friedman; H V Gelboin
Journal:  Br J Clin Pharmacol       Date:  1986-08       Impact factor: 4.335

View more
  1 in total

1.  Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man.

Authors:  D Sesardic; A R Boobis; B P Murray; S Murray; J Segura; R de la Torre; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.